Patents Assigned to Tonix Pharma Holdings Limited
  • Patent number: 11026898
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: June 8, 2021
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Seth Lederman, Marino Nebuloni
  • Patent number: 10946027
    Abstract: Disclosed herein is an oxalate salt/co-crystal (tianeptine oxalate) of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine) as shown in Formula I:
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: March 16, 2021
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Stefano Luca Giaffreda, Enrico Modena, Serena Fabbroni, Michel Chiarucci, Mark T. Edgar
  • Patent number: 10864176
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: December 15, 2020
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Patent number: 10864175
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: December 15, 2020
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Patent number: 10736859
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: August 11, 2020
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Patent number: 10722478
    Abstract: The present invention relates to methods for the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, fibromyalgia, Fabry's disease, Parkinson's disease, or traumatic brain injury, using cyclobenzaprine. The present invention further relates to a biomarker for the therapeutic effects of a cyclobenzaprine treatment.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: July 28, 2020
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Seth Lederman, Herb Harris
  • Patent number: 10449203
    Abstract: Disclosed herein is an oxalate salt/co-crystal (tianeptine oxalate) of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine) as shown in Formula I:
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: October 22, 2019
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Stefano Luca Giaffreda, Enrico Modena, Serena Fabbroni, Michel Chiarucci, Mark T. Edgar
  • Patent number: 10357465
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: July 23, 2019
    Assignee: TONIX PHARMA HOLDINGS LIMITED
    Inventors: Seth Lederman, Marino Nebuloni
  • Patent number: 10322094
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: June 18, 2019
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Publication number: 20190175525
    Abstract: Compositions comprising cyclobenzaprine, and methods for the treatment or prevention of agitation, psychosis and/or cognitive decline and associated symptoms thereof in dementia and other neurodegenerative conditions.
    Type: Application
    Filed: December 11, 2018
    Publication date: June 13, 2019
    Applicant: Tonix Pharma Holdings Limited
    Inventors: Herbert W. Harris, Seth Lederman
  • Publication number: 20190022030
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Application
    Filed: September 24, 2018
    Publication date: January 24, 2019
    Applicant: Tonix Pharma Holdings Limited
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Publication number: 20190022031
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Application
    Filed: September 24, 2018
    Publication date: January 24, 2019
    Applicant: Tonix Pharma Holdings Limited
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Patent number: 10117936
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 6, 2018
    Assignee: TONIX PHARMA HOLDINGS LIMITED
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Patent number: 9956188
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: May 1, 2018
    Assignee: TONIX PHARMA HOLDINGS LIMITED
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Patent number: 9918948
    Abstract: The present invention relates to methods for the treatment or prevention of symptoms associated with post-traumatic stress disorder, and related pharmaceutical compositions. Of particular interest are pharmaceutical compositions comprising a very low dose of cyclobenzaprine, alone, or in combination with an alpha-1-adrenergic receptor antagonist, a beta-adrenergic antagonist, an anticonvulsant, a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: March 20, 2018
    Assignee: TONIX PHARMA HOLDINGS LIMITED
    Inventors: Seth Lederman, Herbert Harris
  • Patent number: 9636408
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 2, 2017
    Assignee: TONIX PHARMA HOLDINGS LIMITED
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Patent number: 9474728
    Abstract: The present invention relates to methods for the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, fibromyalgia, Fabry's disease, Parkinson's disease, or traumatic brain injury, using cyclobenzaprine. The present invention further relates to a biomarker for the therapeutic effects of a cyclobenzaprine treatment.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: October 25, 2016
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Seth Lederman, Herb Harris
  • Patent number: 9403755
    Abstract: The invention relates to a purified Isometheptene compound comprising the structure according to Formula (I), or a hydrochloride, or a pharmaceutically acceptable addition salt thereof. In particular, the disclosure relates to the synthesis, purification and characterization of an Isometheptene isomer mucate crystal 2, wherein the Isometheptene isomer 2 is stereochemically characterized as (R)-enantiomer, respectively. The Isometheptene (R)-enantiomer activity indicates a selective centrally acting selective ligand for Imidazoline subtype 1 (I1) receptor sites; and more specifically, the disclosure provides an antihypertensive composition for treatment of migraine and other neurovascular or neurogenic pain from abdominal distress. (R)-Isometheptene enantiomer or isomer 2 may be an anti-hypertensive agent with lower side effects than the racemate form. Therefore (R)-Isometheptene is believed to be effective against episodic tension-type headaches (ETTH).
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: August 2, 2016
    Assignee: TONIX PHARMA HOLDINGS LIMITED (BERMUDA)
    Inventors: Seth Lederman, Bruce Daugherty, Leland J. Gershell, Darryl Rideout, Andrew Kawasaki
  • Patent number: 9314469
    Abstract: A method of treating corticosteroid-induced cognitive impairment comprises administering an effective amount of at least one compound of formula I, or pharmaceutically acceptable salts thereof, to a subject in need of such treatment. Formula I is: wherein: A is a bridge selected from the following radicals: —(CH2)m—, —CH?CH—, —(CH2)p—O—, —(CH2)p—S—, —(CH2)p—SO2—, —(CH2)p—NR1— and —SO2—NR2—, and wherein: m is an integer of from 1 to 3 inclusive; p is an integer selected from 1 and 2; R1 is selected from the group consisting of hydrogen and C1-C5 alkyl; and R2 is C1-C5 alkyl; X and Y are independently selected from the group consisting of hydrogen and halogen; R and R? are independently selected from the group consisting of hydrogen and C1-C5 alkyl; n is an integer from 1 to 12 inclusive; and * denotes an asymmetric carbon.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: April 19, 2016
    Assignee: Tonix Pharma Holdings Limited
    Inventor: Gregory M. Sullivan